- Recent Funding
- Investors
- Eli Lilly
Eli Lilly portfolio
Eli Lilly has 21 portfolio companies on record at Recent Funding, with 8 investments in the last 12 months.
About this page
It led 1 of the 18 rounds it joined. Its most recent investment on record is Oyster Therapeutics's $60M Series A round in November 2026, alongside Global Brain Corporation, 4BIO Capital, Mass General Brigham Ventures and 5 others. By category, its portfolio leans toward Health and bio (21) and Robotics and hardware (2). It has co-invested with Mission BioCapital, Pfizer Venture Investments and Novo Holdings, most often Mission BioCapital (3 rounds).
What Eli Lilly invests in
- Health and bio · 21 · 100%
- Robotics and hardware · 2 · 10%
- Manufacturing and industrial · 2 · 10%
- Education · 2 · 10%
- Logistics and mobility · 2 · 10%
- Fintech · 1 · 5%
- Insurance · 1 · 5%
- Consumer and social · 1 · 5%
Eli Lilly recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| Series A · $60M | Global Brain Corporation, 4BIO Capital (lead), Mass General Brigham Ventures +5 | ||
| Series B+ · $108M | Scale Venture Partners, The General Partnership, Paychex +6 | ||
| Seed · $33M | 4BIO Capital (lead), AbbVie, BrightEdge - American Cancer Society +3 | ||
| Series B+ · lead | none named | ||
| Series B+ · $315M | Fidelity Management & Research Company, Morningside, Abingworth +15 | ||
| Seed · $14M | Cambridge Innovation Capital, Johnson & Johnson Innovation (lead), Cambridge Enterprise Ventures +5 | ||
| Series B+ · $435M | NFDG Ventures, Thrive Capital, Greenoaks +6 | ||
| Series A · $70M | Khosla Ventures (lead), Illinois Ventures, Cornucopian Capital +3 |
How Eli Lilly invests
Eli Lilly portfolio companies
OOyster Therapeutics$60MSeries A · Nov 2026
TThatch$108MSeries B+ · Sep 2026
CCloverleaf Bio$33MSeed · Sep 2026
OOuraSeries B+ · Jul 2026
AAdvanCell$315MSeries B+ · Jul 2026
TTRIMTECH Therapeutics$14MSeed · Jun 2026
NNewLimit$435MSeries B+ · Jun 2026
EExcelsior Sciences$70MSeries A · Dec 2025
TTherini Bio$39MSeries A · May 2025
AAugustine Therapeutics$85MSeries A · Mar 2025
AAmpersand Biomedicines$65MSeries B+ · Mar 2025
OOrbis Medicines$93MSeries A · Jan 2025
MMyricx Bio$120MSeries A · Jul 2024
MMariana Oncology$175MSeries B+ · Sep 2023
CCrossbow Therapeutics$80MSeries A · Jul 2023
AArkuda Therapeutics$64MSeries B+ · Feb 2022
FFlare Therapeuticsbacker
GGrove Biopharmabacker
PPersist AIbacker
VViaNautisbacker
SSeawolf Therapeuticsbacker
| Company | Round with Eli Lilly | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series A · $60M | $60M | Nov 10, 2026 Series A |
Fintech |
Series B+ · $108M | $186M | Sep 15, 2026 Series B+ |
Health and bio |
Seed · $33M | $33M | Sep 8, 2026 Seed |
Health and bio |
Series B+ · lead | $1.24B | Jul 15, 2026 Series B+ |
Health and bio |
Series B+ · $315M | $439.5M | Jul 15, 2026 Series B+ |
Health and bio |
Seed · $14M | $45M | Jun 23, 2026 Seed |
Health and bio |
Series B+ · $435M | $650M | Jun 2, 2026 Series B+ |
Health and bio |
Series A · $70M | $165M | Dec 3, 2025 Series A |
Health and bio |
Series A · $39M | $56M | May 21, 2026 Series A |
Health and bio |
Series A · $85M | $103.17M | Mar 24, 2025 Series A |
Health and bio |
Series B+ · $65M | $65M | Mar 19, 2025 Series B+ |
Health and bio |
Series A · $93M | $121M | Jan 6, 2025 Series A |
Health and bio |
Series A · $120M | $120M | Jul 8, 2024 Series A |
Health and bio |
Series B+ · $175M | $175M | Sep 7, 2023 Series B+ |
Health and bio |
Series A · $80M | $157M | Mar 26, 2026 Series B+ |
Health and bio |
Series B+ · $64M | $108M | Feb 10, 2022 Series B+ |
Health and bio |
backer | $167M | Jun 30, 2026 Series B+ |
Health and bio |
backer | $30M | Apr 23, 2025 Series A |
Health and bio |
backer | $16.5M | May 19, 2025 Series A |
Health and bio |
backer | $25M | Oct 31, 2024 Series A |
Health and bio |
backer | $100M | Nov 16, 2026 Seed |
Most frequent co-investors
MMission BioCapital3 shared rounds · last Nov 10, 2026
PPfizer Venture Investments3 shared rounds · last Jun 23, 2026
NNovo Holdings3 shared rounds · last Mar 24, 2025
44BIO Capital2 shared rounds · last Nov 10, 2026
QQuiet Capital2 shared rounds · last Sep 15, 2026
SSanofi Ventures2 shared rounds · last Jul 15, 2026
AAbingworth2 shared rounds · last Jul 15, 2026
BBrandon Capital2 shared rounds · last Jul 15, 2026
SSV Health Investors2 shared rounds · last Jul 15, 2026
DDementia Discovery Fund2 shared rounds · last Jun 23, 2026
KKleiner Perkins2 shared rounds · last Jun 2, 2026
HHuman Capital2 shared rounds · last Jun 2, 2026
Similar investors
SSands Capital Ventures21 companies · 8 deals in 12 mo
CCathay Innovation21 companies · 4 deals in 12 mo
FForbion Capital Partners21 companies · 4 deals in 12 mo
PPolaris21 companies · 4 deals in 12 mo
MMirae Asset Capital22 companies · 9 deals in 12 mo
OOrbiMed22 companies · 8 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Share is of the 18 rounds on Recent Funding that name Eli Lilly. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Eli Lilly, which is a subset of its real portfolio. API: /api/v1/investors/eli-lilly (get a free API key). More: the most active VC firms and new venture capital funds.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy